Dermatology · Pittsburgh, PA
NPI
1043283229
Since 2006
Specialty
Dermatology
Code 174400000X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
3601 5th Ave, Suite 5a Falk Medical Building
Pittsburgh, PA, 15213
Phone (412) 648-3263
Groups this clinician bills Medicare through
Medicare paid, 2024
$21K
513 services
Medicare patients, 2024
224
Average age 73
Drug cost, 2024
$4.5M
1,471 prescriptions
Company payments, 2025
$86K
From 23 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Laura Ferris was code 99213 (office e&m - established), 84 times for 75 patients. In total Laura Ferris billed 513 services in 26 codes, and Medicare paid $21K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-03-25.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 84 | 75 | $43.76 | $3,676 |
| 17003 Destruction Skin Lesion | Office | 74 | 22 | $2.93 | $217 |
| 99214 Office E&M - Established | Office | 62 | 56 | $60.02 | $3,721 |
| 17000 Destruction Skin Lesion | Office | 43 | 41 | $33.07 | $1,422 |
| 11102 Skin Biopsy | Office | 32 | 31 | $28.29 | $905 |
| 99214 Office E&M - Established | Facility | 23 | 19 | $61.57 | $1,416 |
| 99213 Office E&M - Established | Facility | 22 | 19 | $38.57 | $848 |
| 17110 Destruction Skin Lesion | Office | 21 | 21 | $45.03 | $946 |
| 99203 Office E&M - New | Office | 12 | 12 | $72.51 | $870 |
| 99204 Office E&M - New | Office | 11 | 11 | $109.86 | $1,208 |
| 11102 Skin Biopsy | Facility | 11 | 11 | $21.91 | $241 |
| 17000 Destruction Skin Lesion | Facility | 11 | 11 | $31.94 | $351 |
| 12032 Wound Repair - All Levels | Office | 11 | 11 | $117.55 | $1,293 |
By year: 2022 $27K for 588 services; 2023 $28K for 607 services; 2024 $21K for 513 services.
Medicare prescription drug claims, 2024
In 2024, the drug Laura Ferris prescribed most often to Medicare patients was Clobetasol Propionate, with 173 prescriptions and refills. In total Laura Ferris wrote 1,471 Medicare prescriptions that cost $4.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Clobetasol Propionate Generic | 173 | 175 | 80 | $4,862 |
| Triamcinolone Acetonide Generic | 155 | 170 | 86 | $1,732 |
| Ketoconazole Generic | 132 | 143 | 52 | $1,881 |
| Methotrexate Methotrexate Sodium | 115 | 173 | 31 | $1,565 |
| Tremfya Guselkumab | 48 | 90 | Under 11 | $645K |
| Skyrizi Pen Risankizumab-Rzaa | 43 | 112 | 12 | $898K |
| Fluorouracil Generic | 43 | 44 | 38 | $2,549 |
| Humira(Cf) Pen Adalimumab | 36 | 36 | Under 11 | $409K |
| Skyrizi Risankizumab-Rzaa | 36 | 101 | 11 | $724K |
| Taltz Autoinjector Ixekizumab | 34 | 34 | Under 11 | $231K |
| Valacyclovir Valacyclovir Hcl | 31 | 35 | 14 | $424 |
| Dupixent Syringe Dupilumab | 30 | 30 | Under 11 | $119K |
| Acitretin Generic | 27 | 39 | Under 11 | $6,733 |
| Cosentyx Sensoready (2 Pens) Secukinumab | 27 | 27 | Under 11 | $195K |
| Ciclopirox Ciclopirox Olamine | 25 | 38 | Under 11 | $309 |
Brand drugs: 455 claims; generic drugs: 1,016 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Laura Ferris $86K ($84K in general payments such as food, travel and fees and $1,736 for research) from 23 companies. The largest payer was Boehringer Ingelheim Pharma GmbH & Co.KG with $12K.
| Company | Payments | Amount |
|---|---|---|
| Boehringer Ingelheim Pharma GmbH & Co.KG | 4 | $12K |
| Arcutis Biotherapeutics, Inc. ARQT | 4 | $9,943 |
| Boehringer Ingelheim International GmbH | 3 | $9,908 |
| Regeneron Pharmaceuticals, Inc. REGN | 12 | $9,678 |
| Janssen Biotech, Inc. JNJ | 8 | $9,142 |
| E.R. Squibb & Sons, L.L.C. BMY | 10 | $6,888 |
| Almirall LLC | 4 | $6,750 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $6,525 |
| Pfizer Inc. PFE | 1 | $6,200 |
| Sun Pharmaceutical Industries Inc. SUNPHARMA.NS | 4 | $3,420 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.